Tagged with Opinion

Opinion AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the ongoing coronavirus pandemic.   Like the rest of society, executive and scientific teams working in the US generic and biosimilar pharmaceutical industries have never experienced anything quite…

Opinion Blue Spoon Consulting’s John G. Singer* provides a thought-provoking outline of how the global health economy needs to evolve a new ‘systems framework’ to deal with the complexity and interconnectedness of healthcare today.   We need to unleash a new set of capabilities designed by a different level of thinking…

Europe EFPIA’s Nathalie Moll highlights how Europe can reverse its decline in the global medical research standings and once again make the continent a world leader in medical innovation.   If the content of the Pharmaceutical Strategy undermines the ambition of the Industrial Strategy then there is a very real, immediate…

Canada Dr Neil Cashman looks at the potential impact of US FDA approval for Biogen’s aducanumab on the search for Alzheimer’s Disease (AD) treatments, and how Canada is playing a leading role in the development of the next generation of AD therapies.   We’re at the advent of a potential landmark…

Opinion Francois Sandre, Head of Asia & JPAC for Sanofi Pasteur outlines the importance of a sustainable global vaccine ecosystem and why a value-based approach, ensuring a steady supply of vaccines, and encouraging innovation are all crucial to meeting the public health goals of the future.   Vaccination is one of…

Opinion Regular PharmaBoardroom contributor David Crean looks at how the ongoing global coronavirus outbreak has impacted the global economy, how the biopharmaceutical industry is responding, and what the longer-term consequences of the crisis and responses to it will be.   The latest disruptor to global health and the economy is the…

Opinion Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in January 2020 may mark a turning point for greater access to generic and biosimilar medicines globally.   US trading partners should take note. There is no longer a…

Opinion Brendan Shaw outlines the long road still to travel to meet the UN Sustainable Development goal of ensuring basic healthcare financing for every citizen in the world by 2030 and the vital role that the private sector must play in attempting to meet this challenge.   The majority of developing…

China Eurasia Group’s Aditya Bhattacharji examines the unfolding coronavirus outbreak, the prospects for China’s political and economic stability, and how healthcare firms should think about the path forward. China appears to be ground zero for a public health experiment with no recent analogues. The situation—in terms of social and economic dislocation—deteriorates…

USA Takeda’s Jessica S. Scott examines the steps already being taken to bring greater patient engagement to drug development and the regulatory decision-making process in the USA; as well as what more needs to be done in this crucial area.   Steps Taken by FDA Under the Food and Drug Administration…

USA The Association for Accessible Medicines’ Chip Davis outlines the ways in which the US Medicare programme needs updating in order to promote generic and biosimilar competition and therefore increase patient access to more affordable medicines.   In this election year I hope that the candidates will lay out their solutions…

Opinion Health Catalyst’s Elia Stupka explains why and how patients must be kept at the centre of the healthcare systems of the future, even as they become increasingly data-driven.   Healthcare data is seen by many as the ‘new goldmine,’ with many businesses in this field evaluated and sold at a significant…